

Nordic Urothelial Cancer Group



Newsletter Date
Volume 1, Issue2




GREETINGS

Recruitment is going well and we have almost 500 subject in the study! Thank you all for that. We are very close to have 500 subject in the study, and that is when we are going to start to write our first publication!

However, we noticed some lacking information in patient datas that are marked as completed. We hope you check your centre's data once more and fill in the gaps if necessary and only after that mark the subject completed.

Later in the summer/fall we will go through all the patient information and send reminders if any necessary data is missing. If all the required data is filled in completely, we will lock the patient data.

Recruitment status:

| | |
|---|-----|
|  | 88 |
|  | 81 |
|  | - |
|  | 313 |
|  | 10 |



GREETINGS FROM THE PRINCIPAL INVESTIGATOR

Dear **Norcys** investigators and all involved in the study. It was great to see some of you during the NUF meeting in Helsinki where we learned that also Norway is starting the study. Erik Skaaheim Haug is the national PI in Norway. With Norway, we have all Nordic countries included.



Denmark has been the most active by far with 5 active centers and >300 included cystectomy patients. Finland is the second with 4 active center and close to hundred patients followed by Sweden with 3 centers. And of course, Iceland as well is very active.

The study is by no means closed for new center and we encourage all centers doing cystectomies to join us! Please contact either myself (peter.bostrom@tyks.fi), our monitor, Dr. Tiia Tikkanen (tiia.tikkanen@utu.fi) or your national coordinator.







We hope to get our first paper out later this year and we plan to publish basic characteristics of the study population to have an idea how cystectomy looks in Nordic countries in 2022. For that we need some data management and the analyses. Prior to the publication we will be of course in contact with each center and everyone can comment the manuscript.


As said, please be active. You may also suggest ideas for new substudies or analyses/publications from our material.

Please, also remember to relax during the summer and have a very relaxing holidays


god sommer, glad sommar, gleðilegt sumar, hyvää kesää !

CURRENT STATISTICS


| | |
|--|------------|
|  | ALL 493 |
|  | FIN 88 |
|  | ICE 10 |
|  | SWE 81 |
|  | NOR 0 |
|  | DEN 313 |




Gender



Pre-operative chemotherapy



Modality



CURRENT STATISTICS

Cystectomy characteristics

| | Overall, N = 501 ¹ | Denmark, N = 351 ¹ | Finland, N = 79 ¹ | Iceland, N = 11 ¹ | Sweden, N = 60 ¹ | p-value ² |
|-------------------------------|-------------------------------|-------------------------------|------------------------------|------------------------------|-----------------------------|----------------------|
| Modality | | | | | | <0.001 |
| Open | 131 (29%) | 34 (10%) | 52 (87%) | 0 (0%) | 45 (82%) | |
| Robot-assisted | 322 (71%) | 293 (90%) | 8 (13%) | 11 (100%) | 10 (18%) | |
| Diversion | | | | | | 0.002 |
| Conduit | 436 (96%) | 321 (97%) | 54 (90%) | 11 (100%) | 50 (94%) | |
| Continent catethrizable stoma | 1 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.9%) | |
| Neobladder | 15 (3.3%) | 9 (2.7%) | 6 (10%) | 0 (0%) | 0 (0%) | |
| Ureterocutaneostomy | 2 (0.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (3.8%) | |
| Urethrectomy | 77 (18%) | 45 (15%) | 13 (22%) | 0 (0%) | 19 (36%) | 0.002 |
| Lymphadenectomy | | | | | | |
| Extended | 264 (58%) | 247 (75%) | 4 (6.9%) | 0 (0%) | 13 (23%) | |
| Limited | 5 (1.1%) | 2 (0.6%) | 2 (3.4%) | 1 (9.1%) | 0 (0%) | |
| None | 22 (4.8%) | 9 (2.7%) | 6 (10%) | 5 (45%) | 2 (3.6%) | |
| Standard | 161 (35%) | 70 (21%) | 45 (78%) | 5 (45%) | 41 (73%) | |
| Super-extended | 2 (0.4%) | 1 (0.3%) | 1 (1.7%) | 0 (0%) | 0 (0%) | |
| Drain | 108 (24%) | 9 (2.8%) | 46 (77%) | 11 (100%) | 42 (81%) | <0.001 |
| Time from skin to skin | 305 (246, 382) | 300 (242, 360) | 256 (222, 306) | 365 (346, 371) | 502 (388, 570) | <0.001 |
| Blood loss | 200 (100, 500) | 200 (100, 300) | 700 (425, 1,100) | 200 (100, 250) | 350 (200, 600) | <0.001 |

¹ n (%); Median (IQR)

² Fisher's exact test; Kruskal-Wallis rank sum test